Mechanisms of Pituitary Tumorigenesis
Mechanisms of Pituitary Tumorigenesis
批准号:
7728998
负责人:
SHLOMO MELMED
金额:
$28.57万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-15 至 2011-06-30
关键词:
AccountingAdrenal Gland HyperfunctionAdrenal GlandsAneuploidyBenignCell Culture TechniquesCell CycleCell Cycle ArrestCell Cycle CheckpointCell Cycle ProteinsCell Cycle RegulationCell ProliferationCellsChromosomal InstabilityClinicalCorticotropinDNA DamageDevelopmentE2F1 geneEndocrine SyndromeEstrogensFailureFunctional disorderG1 PhaseGene ExpressionGeneticGenetic ModelsGenetic TranscriptionGenotypeGonadotropinsGrowthGrowth DisordersHeterozygoteHormonalHormonesHumanHyperplasiaIn VitroInfertilityIntracranial NeoplasmsKnock-in MouseLinkMalignant - descriptorMalignant NeoplasmsMeasuresMediatingMediator of activation proteinMetabolicMitosisModelingMusNeoplasmsPTTG1 genePathogenesisPathway interactionsPenetrancePituitary DiseasesPituitary GlandPituitary Gland AdenomaPituitary NeoplasmsPituitary carcinomaPregnancyProlactinPropertyProteinsRattusRoleSister ChromatidSomatotropinSomatotropin-Releasing HormoneStructureTP53 geneTestingThyroid GlandTissuesTransgenic ModelTumor Cell Lineadenomabasecancer cellgonad functionhormone regulationhuman PTTG1 proteinimprovedinhibitor/antagonistinsightmutantneoplastic cellprematureprotein expressionprotein functionpublic health relevanceresearch studysenescencetumortumor growthtumorigenesis
中文摘要
描述(申请人提供):垂体瘤占颅内肿瘤的15%,是一种临床上无症状或分泌包括催乳素、生长激素、促肾上腺皮质激素等激素的良性单克隆性肿瘤,也可极少分泌促甲状腺激素或促性腺激素。这些腺瘤是临床不孕症、生长障碍和皮质醇增多症或与低垂体症相关的代谢功能障碍的原因。本研究旨在探讨垂体细胞增殖调控紊乱在这些良性腺瘤发病机制中的作用。在第一个目标中,我们将在转基因小鼠垂体肿瘤模型(1GSU.PTTG和Rb杂合子)中研究垂体非整倍体、过早增殖停滞(衰老)、细胞增殖标志和肿瘤发生的机制。遗传和激素诱导的脑下垂体肿瘤发生机制将在这些基因类型和脑垂体细胞培养中进行研究。在第二个目标中,我们将研究人类垂体肿瘤中的DNA损伤、非整倍体的细胞标记和衰老介质。在第三个目标中,我们将通过评估E2F1对Rb小鼠、缺失p53或p21的突变人癌细胞以及人垂体腺瘤中Pttg转录和蛋白表达的诱导,来研究Rb/E2F诱导垂体肿瘤的机制。这些实验的结果将使人们能够进一步深入了解细胞周期控制和生长限制在实验性和人类垂体瘤中的作用,这是它们未能进展为恶性肿瘤的根本原因。这些结果将提高我们对临床内分泌综合征的理解,这些综合征与不孕不育、生长障碍、皮质醇增多或由于垂体功能丧失而导致的肾上腺、甲状腺和性腺功能衰竭有关。公共卫生相关性:该项目将研究实验性垂体瘤模型的生长控制,以及荷尔蒙分泌或临床不分泌的人类垂体瘤。这些实验将深入了解不孕不育、生长障碍或皮质醇亢进的潜在机制,以及由于垂体功能紊乱而导致的甲状腺、肾上腺或性腺功能衰竭。
英文摘要
DESCRIPTION (provided by applicant): Pituitary tumors account for 15% of intracranial neoplasms and are benign monoclonal neoplasms which may be clinically silent or secrete hormones including prolactin, growth hormone, ACTH, or rarely TSH or gonadotropins. These adenomas account for clinical infertility, growth disorders and hypercortisolism or metabolic dysfunctions associated with hypo-pituitarism. This proposal is aimed at exploring the role of disordered pituitary cell proliferation control in the pathogenesis of these invariably benign adenomas. In the first Aim, we will study mechanisms underlying pituitary aneuploidy, premature proliferative arrest (senescence), markers of cell proliferation and tumorigenesis in transgenic models of murine pituitary tumors (1GSU.PTTG and Rb heterozygotes). Mechanisms for both genetic and hormonally induced pituitary tumorigenesis will be studied in these genotypes and in pituitary cell cultures. In the second Aim we will study DNA damage, cellular markers of aneuploidy and senescent mediators in human pituitary tumors. In the third Aim we will study mechanisms for Rb/E2F induction of pituitary tumors by assessing E2F1 induction of Pttg transcription and protein expression in Rb mice, in mutant human cancer cells devoid of p53 or p21, as well as in human pituitary adenomas. Results of these experiments will enable further insights into the role of cell cycle control and growth constraint of experimental and human pituitary tumors, underlying their failure to progress to malignancy. The results will improve our understanding of clinical endocrine syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function. PUBLIC HEALTH RELEVANCE: This project will study growth control of experimental pituitary tumor models, as well as hormone-secreting or clinically non-secreting human pituitary tumors. These experiments will provide insight into mechanisms underlying development of infertility, growth disorders or hypercortisolism, as well as failure of thyroid, adrenal or gonadal function due to disordered pituitary function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)
-
批准号:10003845
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:10578571
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:9893867
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit
-
批准号:8773516
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2014
-
负责人:SHLOMO MELMED
-
依托单位:
Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)
-
批准号:7935157
-
项目类别:
-
资助金额:$955.29万
-
财政年份:2010
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7606126
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7606124
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2007
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7376014
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7376016
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7206322
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7206320
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6599784
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7008190
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7172931
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6833420
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Pituitary Tumor Surveillance: Pathogenetic Correlation
-
批准号:7042064
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6710585
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for Pituitary Tumorigenesis
-
批准号:7042061
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Information Technology for Human Subjects Protection
-
批准号:6591413
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
Gordon Research Conference on Prolactin
-
批准号:6623298
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位: